MBX Stock News & Catalysts

FEATURED

MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights

New

Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track

Summary

Nov 9, 2026, 4:01 PM ·Globe Newswire

RECENT

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The federal government's October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action

Nov 5, 2026, 9:20 AM ·Globe Newswire

MBX Biosciences to Participate in Upcoming November Investor Conferences

CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel

Oct 13, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences to Participate in Upcoming Investor Conferences

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of

Sep 9, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

CARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of

Sep 8, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support once-weekly

Aug 27, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a

Aug 6, 2026, 8:00 AM ·Globe Newswire

Attovia Therapeutics Appoints John W. Smither to Board of Directors

SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for

Jul 15, 2026, 8:30 AM ·Globe Newswire

MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel

Jul 13, 2026, 4:15 PM ·Globe Newswire

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium

Jun 12, 2026, 7:00 AM ·Globe Newswire

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide

Jun 1, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel

May 26, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated, only one event of

May 11, 2026, 7:00 AM ·Globe Newswire

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief

May 7, 2026, 8:00 AM ·Globe Newswire

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel

May 7, 2026, 7:00 AM ·Globe Newswire

MBX Biosciences, Inc. Common Stock MBX · News